3 212

Cited 23 times in

A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis

 Park H.S.  ;  Rha S.Y.  ;  Kim H.S.  ;  Hyung W.J.  ;  Park J.S.  ;  Chung H.C.  ;  Noh S.H.  ;  Jeung H.-C. 
 ONCOLOGY, Vol.80(1-2) : 142-150, 2011 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms/blood ; Bone Neoplasms/pathology ; Bone Neoplasms/secondary* ; Bone Neoplasms/therapy ; Carcinoembryonic Antigen/blood ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/secondary ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Stomach Neoplasms/blood ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology* ; Stomach Neoplasms/surgery ; Survival Rate ; Time Factors ; Young Adult
Bone metastasis ; Gastric cancer ; Prognostic factor
BACKGROUND: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. METHODS: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. RESULTS: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). CONCLUSION: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
Hyung, Woo Jin(형우진) ORCID logo https://orcid.org/0000-0002-8593-9214
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.